Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 12/20 | 0.37 |
| ▸ | JAK1 | P23458 | 9/20 | 0.37 |
| ▸ | JAK2 | O60674 | 11/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31403553 | 0.95 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL2792645 | 0.95 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL4062175 | 0.91 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2JAK3JAK1JAK2 | |
| SCHEMBL14241707 | 0.89 | LMNA (0.47) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL3313504 | 0.87 | POLB (0.42) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL3636344 | 0.82 | CHEK2 (0.39) | USP30JAK3JAK1JAK2 | |
| SCHEMBL8123112 | 0.78 | JAK2 (0.48) | LMNASMN1; SMN2JAK3JAK2 | |
| SCHEMBL17141821 | 0.78 | LMNA (0.40) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL4037461 | 0.78 | LMNA (0.40) | LMNASMN1; SMN2USP30JAK3JAK1 | |
| SCHEMBL17316407 | 0.78 | GBA1 (0.50) | LMNASMN1; SMN2USP30JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | claimed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | claimed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | claimed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | BOLIN DAVID ROBERT | 2010-07-01 | — | — | US | disclosed |
| US-7714126-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168419-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | LMNA 4364/4885SMN1; SMN2 4066/4885USP30 2677/4885 |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | LMNA 4698/4885SMN1; SMN2 4749/4885USP30 2018/4885 |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | LMNA 4206/4885SMN1; SMN2 4259/4885USP30 2669/4885 |
| US-20100190979-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT2, DGAT1, LCAT | LMNA 4364/4885SMN1; SMN2 4066/4885USP30 2677/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | LMNA 4364/4885SMN1; SMN2 4066/4885USP30 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.